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SUMMARY
This first report from the Beckley Foundation Drug Policy Programme (BFDPP) discusses the global drug control system -
particularly the role of the United Nations – and the challenges confronting drug policy. It argues that the current system is
not achieving its stated objective: to eradicate completely – or even substantially reduce – illicit drug markets. On the
contrary, over four fifths of the 92 countries that reported on progress to the UN Office on Drugs and Crime said that drug
use in their populations was either not coming down or – in the majority of cases – was still going up. 
The BFDPP is calling for a fundamental review of the impact of this global framework. The overarching objectives of global
drug policy should be to reduce crime and nuisance, death, physical and mental illness, damage to children and families and
failure in education and employment resulting from drug use. This report will ask whether these objectives are being
achieved and which strategies are most likely to deliver positive results in the future.
It is concluded that the drug free world currently sought by the UN is an impossible ideal, but a world in which far less
harm is caused as a result of the production, trafficking and consumption of drugs is both an inspiring ideal and an
achievable objective.
THE GLOBAL SYSTEM
Since the 1920s, the international community has agreed to
systems of prohibition for a wide range of psychoactive
substances, including heroin, cocaine and cannabis. The
current framework for this drug control system is enshrined in
a set of three landmark United Nations (UN) Conventions:
• The Single Convention on Narcotic Drugs 1961.
• The Convention on Psychotropic Substances 1971. 
• The Convention against the Illicit Traffic in Narcotic Drugs
and Psychotropic Substances 1988 (see box 1).
These Conventions limit the acceptable uses of narcotic and
psychotropic substances to medical or research purposes and
call on Member States to otherwise prohibit the production,
distribution and use of psychoactive drugs. 
The Conventions have been signed and ratified by most UN
Member States. This is a remarkable diplomatic achievement.
It shows a high level of international consensus on a complex
policy issue that impacts on different societies in different ways.
There is near universal recognition of the gravity of ‘the drug
problem’ and a shared recognition that it has an irreducibly
global dimension. 
But there are substantial differences over the content and
trajectory of drug policy too. Consider three points:
1 Different states have pursued the implementation of drug
prohibition with varying degrees of enthusiasm. These
range from the strong enforcement of highly punitive drug
laws (including the use of the death penalty in countries
such as Thailand and Saudi Arabia) to official tolerance of
widespread coca use in some South American countries and
(increasingly) of cannabis use in parts of Europe. 
2 There are differences between and within states on the
relative importance of enforcement, treatment, prevention
and social inclusion. Some jurisdictions continue to focus
all their efforts on reducing the supply of drugs. Others
accept that a significant proportion of their populations will
use drugs despite their law enforcement efforts and while
not condoning drug use, are looking at measures to reduce
the harm that results from it. 
3 The effectiveness of existing drug policies is – to a growing
extent – being monitored and evaluated by the UN,
regional organisations (such as the EU) and national
governments. As the evaluation of policy has spread and
become more sophisticated, questions are being raised
about the cost-effectiveness of the established frameworks
and there is increasing divergence of opinion on the way
forward.
These differences have contributed to sharp diplomatic
exchanges between individual Member States at the UN – and
to some interesting debates within countries – but they have
not yet led to any serious review of existing policies in official
international settings. Recently, there has been a greater
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emphasis on demand reduction (treatment and prevention) in
international drug policy, but the policy horizon nonetheless
continues to be dominated by law enforcement (national and
international) with the aim of eliminating – or, at least,
substantially reducing – the use and availability of illicit
psychoactive drugs. 
The growing tensions between inflexible interpretations of
some of the existing UN orthodoxies and the practices of some
Member States are exhibited, once again, in the 2003 Annual
Report from the International Narcotics Control Board
(INCB), which was published in March 2004. The Canadian
Government is condemned for approving the establishment of
a drug injecting room in Vancouver. Concern is expressed
about the ‘relaxation’ of cannabis laws in some European
countries. A more general worry is expressed about what is
viewed by the INCB as ‘ambiguity towards drug abuse … in
countries in Western Europe’ (INCB, 2004). It should be
noted that there are a number of more progressive strands to be
welcomed in the INCB’s Annual Report too. For example, the
discussion of the links between drugs and crime highlights the
need for effective demand reduction programmes and the
importance of referring drug dependent people for treatment
through the justice system as an alternative to incarceration.
But in many parts of the world, local evidence-based practice is
increasingly at odds with what is often excessively rigid
enforcement of the global control system. 
The cost of pursuing an approach to drug policy that has
concentrated on the supply side (and which has marginalised
demand and harm reduction) has not been cheap. Both
governments and international agencies continue to dedicate
significant budgets to the enforcement of the global drug
control system. Recent estimates for the United States are that a
total of over $30 billion per year of taxpayers’ money is being
spent on the enforcement of the drug laws. The equivalent
estimate for the United Kingdom is over £1 billion. Estimates
of the global community’s spending over a 3 years period on
reducing the amount of coca grown in Colombia alone range
from under $2 billion to over $6 billion. Whatever the exact
figure, these investments are substantial. Perhaps this level of
expenditure would be justifiable if the current approach were
significantly reducing prevalence. But it isn’t. So, isn’t it time to
rethink our tactics? 
The UN  Secretary General, Kofi Annan, speaking at the
opening of the UN’s Special Session on the World Drug
Problem in 1998 (UNGASS), declared that the international
community’s mission was ‘to create the momentum for a drug-
free world in the twenty-first century’.1 In April 2003, progress
was reviewed in Vienna at a meeting of the Commission on
Narcotic Drugs (CND) - the UN body that oversees global
drug policy. This meeting concluded with a reiteration and
defence of the existing framework. Antonio Costa, the
Executive Director of the UN Office on Drugs and Crime
(UNODC), proclaimed that the UN was making ‘significant
progress towards still distant goals’. 
This claim is, of course, highly controversial. Indeed, it is very
difficult to reconcile with the findings of the UN’s own report
Global Illicit Drug Trends 2003. Of the 92 countries reporting
to the UNODC in 2001:
• 5% reported a ‘large decrease’ in drug abuse;
• 10% ‘some decrease’;
• 11% a ‘large increase’;
• 37% ‘some increase’; and
• 37% no significant change or ‘stability’ 
(UNODC 2003, p 104). 
So, only 15% reported decreases, while 85% reported that
things had either remained the same or had got worse. With
regard to particular substances:
• 21% reported an increase of crack use;
• 36% of ecstasy use;
• 36% of heroin use;
• 46% of cocaine use;
• 50% of amphetamine use; and
• 54% reported an increase of cannabis use 
(UNODC, 2003, p 105).
Against this background, Georges Estievenart, Executive
Director of the European Monitoring Centre for Drugs and
Drug Addiction (EMCDDA) has recently commented that
‘overall, the drug use trend remains upwards and new problems
are emerging’.2
There are then some significant discrepancies in the assessment
of international drug policies – or at the very least, some
marked differences in emphasis. What is beyond reasonable
dispute is that the UN strategy is failing to make satisfactory
progress against its own targets, raising questions about the
appropriateness and realism of those goals themselves. 
BOX 1
THE UN SYSTEM
Single Convention on Narcotic Drugs, 1961 
This Convention aims to combat drug abuse by coordinated
international action. There are two forms of intervention and
control that work together. First, it seeks to limit the
possession, use, trade in, distribution, import, export,
manufacture and production of drugs exclusively to medical
and scientific purposes. Second, it combats drug trafficking
through international cooperation to deter and discourage
drug traffickers. 
Convention on Psychotropic Substances, 1971 
The Convention establishes an international control system
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for psychotropic substances. It responded to the
diversification and expansion of the spectrum of drugs of
abuse and introduced controls over a number of synthetic
drugs according to their abuse potential on the one hand and
their therapeutic value on the other. 
Convention against the Illicit Traffic in Narcotic Drugs
and Psychotropic Substances, 1988
This Convention provides comprehensive measures against
drug trafficking, including provisions against money
laundering and the diversion of precursor chemicals. It
provides for international cooperation through, for example,
extradition of drug traffickers, controlled deliveries and
transfer of proceedings. 
The key UN bodies
The United Nations Office on Drugs and Crime 
The UNODC is the key international body in developing
and implementing policy to deal with illicit drugs and
international crime. It has approximately 500 staff members
worldwide and relies on voluntary contributions, mainly from
the governments of UN Member States, for 90% of its
budget. Antonio Maria Costa is the current Executive
Director of the UNODC.
The Commission on Narcotic Drugs (CND) 
Established in 1946, this is the central policy making body
with responsibility for drug-related issues. It is composed of
53 countries and meets annually in Vienna in March.
The International Narcotics Control Board (INCB)
Established by the 1961 Convention in 1968, this is the
quasi-judicial control body responsible for monitoring the
implementation of the UN drug conventions. The INCB
ensures that adequate legal supplies of controlled drugs are
available for medical and scientific purposes. The Board also
makes certain that no leakage from licit sources of drugs to
illicit trafficking occurs. It identifies and helps to correct
weaknesses in drug control systems and determines which
chemicals used to illicitly manufacture drugs should be under
international control. Its members are elected by ECOSOC
(the UN Economic and Social Council) from nominees
submitted by member states and the World Health
Organisation (WHO).
HOW MUCH PROGRESS 
HAS BEEN MADE?
Before measuring progress – as subsequent reports from the
BFDPP will do – it is necessary to ask ‘against which
objectives?’ 
There is room for legitimate disagreement about the goals of
drug policy, and the UN itself has never articulated a clear list
of the objectives of international drug control. However, it is
possible to arrive at some definite conclusions. In particular, as
noted above, it is clear on reading the UN Conventions – and
subsequent political declarations from the CND – that the
primary objective of international drug policy has been to
reduce substantially, or even to eradicate completely, illicit
markets for controlled substances. Measuring global drug
policy over the past 40 years against these internal criteria, the
conclusion that it has failed on its own terms is unavoidable. 
Consider the evidence. It is true that the production of opium
and coca – crops that are associated with some of the most
problematic drug use – has stabilised since the mid-1990s.
However, this stabilisation has occurred at high levels after a
dramatic increase in the recent past. Production of opium rose
steeply in the 1980s and 1990s. There was a sharp rise in coca
production in the 1970s and 1980s (see Fazey C and Lloyd C,
2003).3 The UNODC’s Global Illicit Drug Report 2003
concludes that the cultivation of cannabis has continued to
increase. In addition, there is on-going expansion in the
production and trafficking of ‘amphetamine-type substances’
(ATSs) – that is, amphetamines, methamphetamines and
ecstasy (UNODC, 2003, pp 10-11). This last phenomenon
shows how ‘the drug problem’ has changed over the past 30
years with changes in consumption patterns and the availability
of different psychoactive substances – for example, with the
spread of crack cocaine in the 1980s and 1990s.
The available data on consumption tells a similar story. As
noted above, despite global prohibition, an estimated 200
million people broke the law in their respective countries (often
risking harsh criminal sanctions) and took illicit drugs in 2000-
2001. The world consumption figures over this period break
down as follows: 163 million people worldwide consumed
cannabis, 34 million amphetamines, 8 million ecstasy, 14
million cocaine and 15 million opiates, of which 10 million
took heroin (UNODC, 2003, p 11, pp 101-161, pp 334-
345).4
There are obvious problems with measuring the prevalence of
drug use, but these figures are nonetheless striking – and are, if
anything, likely to be an underestimate of the true situation
(some of these problems are discussed in UNODC, 2003, pp
346-347). While a lack of reliable data means that any claims
about general trends in consumption need to be treated with
caution, there is every reason to think that drug use has
continued to rise on a global scale and has significantly
increased over the four decades that the current system has been
developed and implemented.
There are of course significant variations from region to region
and country to country. A study of these differences can be
highly instructive and will have a vital role to play in the
development of more effective drug policies guided by good –
and avoiding bad – practice. But it is also necessary to highlight
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Two disturbing trends in different parts of the world suggest
that punitive responses are failing to prevent or control
epidemics of new kinds of illicit substance use across the
world: the HIV epidemic in the former Soviet Union and the
methamphetamine problem in South East Asia.
Heroin use in the former Soviet Union  
Between 1991 and 2001 the number of registered drug
addicts in the Russian Federation rose more than tenfold,
from 21.2 to 219.9 per 100,000 inhabitants. In 2001, Russia
again reported a strong increase in the abuse of heroin to the
UNODC. Increasing heroin abuse has driven an HIV
pandemic in the former Soviet Union. In 2003, the total
number of people registered as having HIV was 265,000,
nearly three times as many as in 2000. It is estimated that the
actual figure is probably around 1.5 million. Injecting drug
use is the main form of transmission in Russia followed by
sexual contact. This rise in heroin use has occurred despite the
introduction of tough laws that have significantly increased
penalties for drug offences. These laws have conspicuously
failed to reverse the sharply upward trend in heroin use in this
region (see Grassly N C et al, 2003). See BFDPP Briefing
Paper No 2 for a detailed analysis of recent developments in the
former Soviet Union.
Thailand and the methamphetamine explosion
Methamphetamine is a highly potent psycho-stimulant that
has been consumed for many years in the Far East. More
recently, its manufacture has spread to new countries –
including China, Indonesia, Malaysia, Myanmar, the
Philippines, Singapore and Thailand. The UNODC’s Global
Illicit Drug Trends 2003 includes evidence that suggests that
the number of methamphetamine abusers in Thailand rose
ten-fold from 1993 to 2001 – with around 2.5 million Thai
people saying they have used the drug at some time (5.6% of
the population aged 15 to 64). Methamphetamine use is
associated with high-risk HIV behaviours, social problems
and acute and chronic psychological disturbance (Farrell M
and Marsden J, 2002). The Thai Government, under Prime
Minister Thaksin Shinawatra, recently declared victory in a
year long ‘war’ to rid the country of methamphetamine,
pointing to the arrest of over 90,000 drug suspects, and
claiming that prices have soared more than seven-fold as a
result of the fall in supply. But there is acute international
concern about an estimated 2,500 people who have died in
mysterious circumstances during this campaign, and outside
observers – including the UN – have been sceptical about the
sustainability of reduced availability. Yngve Danling of the
UNODC in Bangkok has commented: ‘it has been a success
if you talk about less availability. On the other hand, I’m
doubtful that Thailand has been able to reduce the demand.
So the question is how sustainable will this be?’ (Aglionby J,
2003). See BFDPP Briefing Paper No 4 for a detailed assessment
of the impact of Thai policy on the methamphetamine problem.
On the basis of a cursory survey of the evidence base, the
overall prognosis for current international drug policy does not
look good. But the picture is not entirely negative. There are
parts of the world where illicit drug use is still a relatively rare
occurrence. In addition, there are examples of drug policies
showing some success in stifling the illicit market. 
In the USA during the 1980s, the prevalence of drug use fell
significantly. In Scandinavia the scale of the illicit drug market
has remained relatively small compared to the rest of Europe,
despite similar conditions. Australia succeeded in creating a
heroin ‘drought’ that lasted through 2002 and into 2003.
While these achievements appear to have been temporary and
seem to be the exception not the rule, it is important to learn
the lessons from them. The BFDPP project will investigate
these experiences and draw out the lessons for policy makers.
This also means asking whether the absence or reduction of
drug problems in some countries has been a result of their anti-
drug programmes, or other cultural, economic, social and
political factors – and if the latter, what these protective factors
are and whether they are ‘exportable’ – at least in principle - to
other areas of the world.
THE DILEMMA 
The challenge for the world community is not simply that an
excessively supply-led approach to drug policy is failing in its
primary objective of eliminating – or substantially reducing -
the use and availability of illicit drugs. In addition, countries –
particularly in the developing world – can be put under
pressure by the international community to adopt an approach
to illicit drugs that has failed elsewhere and which can inhibit
investment in public health measures. Meanwhile, some of the
Member States with the most experience of drug problems
among their populations have changed direction. While these
jurisdictions are not abandoning their law enforcement efforts,
they are now developing complementary policies to reduce the
harm caused by drug use. However, they are sometimes
struggling to reconcile the evidence emerging from their own
programmes with the approaches promoted by the UNODC.
In reality, behind a veneer of consensus, there are growing
tensions within the United Nations itself and between different
UN agencies. 
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Martin Jelsma and Pen Metaal of the Transnational Institute
have recently highlighted fundamental inconsistencies at the
core of the UN drug control programme – tensions between
repression and protection, dogmatism and pragmatism, the
developed and developing world and demand-led and supply-
led approaches. They conclude that ‘consensus seeking’ has
resulted in the creation of a ‘virtual reality … in the conference
halls, as if somehow these different positions all contribute to a
common goal, reinforcing one another, while in fact, some are
incompatible or mutually exclusive’. Moreover, the UN bodies
themselves have different cultures and approaches. The INCB
has acquired a reputation for interpreting the Conventions in a
strict and narrow fashion (for example, issuing a strongly
worded condemnation of the UK Government’s decision to
reclassify cannabis), while other UN agencies, such as
UNAIDS, the World Health Organisation, and the UN
Development Programme have given support to the public
health and development approaches that are viewed with such
suspicion in Vienna.
It has also been claimed that there may be tensions between
international drug policy and the UN Charter of Human
Rights and other legal instruments – notably where
punishments for less serious drug offences are widely regarded
as disproportionate to the gravity of the offence (see for
example, Bewley-Taylor D, 2003). For example, it may be
difficult to reconcile the imprisonment of young people for
drug offences with Article 37 of the UN Convention on the
Rights of the Child, according to which ‘the arrest, detention or
imprisonment of a child … shall be used only as a measure of
last resort and for the shortest appropriate period of time’.
FUTURE POLICY OPTIONS
There is little ground for optimism that current global control
systems will lead to eradication or significant reduction of drug
use. Extensive production, trafficking and consumption of
psychoactive drugs will persist in most parts of the world for
the foreseeable future. That is the reality. Against this
background, an independent review and reassessment of the
ultimate aims of global drug policy and an investigation of the
best means of achieving these objectives based on a detailed and
independent evaluation of good – and less good – practice, is
overdue. This is part of the BFDPP’s mission. 
For us, the challenge is to develop policies and programmes –
nationally and internationally – that can manage the
phenomenon of drug use in ways that minimise the health,
economic, social and political costs. The ‘war against drugs’
approach aimed to eliminate – or, at least, to reduce
substantially – the use of illicit substances through tough and
uncompromising law enforcement. The reality is that this is no
longer a credible objective. The aim of drug policy at the
beginning of the twenty-first century should be to minimise the
harms caused by illicit drugs, with law enforcement, treatment
and prevention all continuing to be important means to this
end. These include direct harms to users, harm to families,
neighbourhoods, communities and societies, as well as the
unintended harms that can result from the implementation of
ill-conceived drug policies, nationally and internationally. 
It is possible to create a list of policy objectives against which
progress can be measured – although there are significant
disagreements on their relative importance. A detailed
taxonomy is provided by MacCoun and Reuter. They
distinguish between harms to users, dealers, intimates,
employers, neighbourhoods and society. They identify four
broad category of harm: ‘health’, ‘social and economic
functioning’, ‘safety and public order’ and ‘criminal justice’.
These categories are further broken down into a vast array of
more specific harms ranging from reduced performance at
work or school to corruption of legal authorities, from mental
and physical illness to interference in source countries, and
from devaluation of arrest as a moral sanction to HIV and
other disease transmission (see MacCoun R and Reuter R
2001, pp 106-107). 
The BFDPP taxonomy of harm (see box 3) provides a simpler
basis for judging the effectiveness of different policies. It shifts
the evaluative emphasis from effectiveness in reducing the use
and production of illicit drugs to effectiveness in reducing the
harm associated with drug use and drug policy. Reducing
prevalence is reconceived as an important  means of reducing
drug-related harm, and not as an end in itself. This does not
mean that high prevalence rates should be accepted as given
and the focus should be on harm reduction instead. Illicit drugs
are harmful, and reducing use is an effective way of reducing
harm. But it does mean that policy makers need to be realistic
about the scope for reducing use and availability; to be guided
by the evidence base in determining effective ways of reducing
prevalence; and be committed to reducing harm to drug users
as well as to reducing the numbers of drug users. We will
develop these ideas further in our next report.
BOX 3 
KEY HARMS RELATED TO DRUGS 
AND DRUG POLICIES
The BFDPP aims to assess the costs and benefits of different
approaches to drug policy across six key dimensions which are
already implicit in many of the relevant international and
national policy documents. 
The aims of policy should be:
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1 To reduce the levels of crime and public nuisance associated
with the production, supply, purchase and use of drugs.
2 To reduce the numbers of deaths that result directly from
the production, supply, purchase and use of drugs.
3 To reduce the number of people suffering physical health
problems as a result of the use of drugs, and particularly
HIV and hepatitis infections.
4 To reduce the number of people suffering mental health
problems and addiction as a result of their use of drugs.
5 To reduce the social costs of drug use, including the impact
on families and children and the numbers of people failing
in education and employment as a result of their use of
drugs.
6 To reduce the damage to the environment as a result of the
production, supply, purchase and use of drugs.
The pursuit of these objectives should respect universal
human rights and, subject to this requirement, local judicial
norms and practices. Policy should also reflect the fact that
different drugs have different consequences in terms of these
harms. An accurate evaluation of the costs associated with
drug use will also require on-going scientific review of the
effects of different psychoactive substances. 
(Thoumi F, 2002, p 172). This presents policy makers with
some difficult practical choices and some profound moral
dilemmas. As Thoumi explains, ‘some constraints cannot give,
but others must be sacrificed. For example to control drugs it
might be necessary to sacrifice individual human rights or the
environment’ (ibid). 
There will always be hard moral and political choices in this
difficult policy area and there is room for informed and
legitimate disagreement about the best way forward. But this
debate should be properly informed and while the BFDPP will
not necessarily succeed in pointing the way forward in a clear
and unambiguous way, it is anticipated that it will be able to do
much to signpost some of the swamps and pitfalls that should
be avoided. 
AN INDEPENDENT REVIEW 
IS OVERDUE
The need for open debate about global drug policy is driven by
three key developments: 
• the lack of progress of the current system 
• the fragmentation of the international consensus on the
way forward and;
• the speed of change of the external environment (for
example, the development of new synthetic drugs).
The aim of the BFDPP is to inform this debate, not to pre-
empt it. This project is not driven by a commitment to any
definite set of policy or political positions, except a concern
about the effectiveness of global drug policy and a belief that
this situation needs to be addressed as a matter of urgency (see
box for a summary of the guiding principles of the BFDPP
programme). 
This is an international humanitarian crisis in its own right.
The human costs of drug abuse and of ill-considered policy
responses to it are immense. Certainly, the international status
quo is hard to defend. Yet, as they confront new drug problems,
more countries are being pressurised into pursuing policies that
have manifestly failed elsewhere. The time is overdue for an
informed, open and mature debate about drug policy at an
international level. The current UN drug strategy runs to 2008
and it is already clear that it will not succeed in its core
objectives. The global systems that have been established in the
past 40 years mean that more evidence is becoming available all
the time on the impact of different policies and initiatives in
different parts of the world. The lessons from this growing
international evidence base need to be learnt. Against this
background, there is a clear need for an independent review
which gives due consideration to the emerging evidence base. 
A number of individuals and groups throughout the world will
have a positive contribution to make to this process. There is
RESPECT FOR LOCAL PRIORITIES 
AND PRACTICES
The BFDPP is not claiming that there is a single correct
solution to ‘the drug problem’, even in principle. There is room
for significant disagreement about the way forward even if there
is agreement that the ultimate aim should be to reduce harm
and that policy should be guided by the best available evidence.
Different areas of the world have different problems and the
consequences of illicit drug use vary greatly from place to place.
Furthermore, the development of drug policy is not simply a
statistical exercise that can be resolved by social scientists. It is a
matter for democratic debate at international level and within
individual countries about political priorities, cultural
commitments and moral values. 
As Reuter and MacCoun point out, the advantages and
disadvantages of different approaches to drug policy will be
unevenly distributed between different segments of society –
and between regions of the world. In addition, how the
different options – and the associated harms and benefits – are
weighed ‘depends on one’s values and on the normative
framework one applies’ (MacCoun R and Reuter P, 2001, pp
11-12). Similarly, Francisco Thoumi has recently commented
that ‘the illicit drug problem has many dimensions: political,
social, moral, public health, economic, environmental, etc.
Every one of these imposes constraints on policy success’
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considerable expertise in policy analysis in the academic sector
which has yet to be fully exploited to review global drug policy.
Throughout the world, non-governmental organisations
(NGOs) combine expertise on drug policy with practical
experience of the realities of tackling drug problems ‘on the
ground’. But, for a variety of reasons, these voices are not
sufficiently heard in the official international forums. 
The BFDPP will seek to draw on this experience and expertise to
inform and broaden out a debate about international drug policy
that has been dominated by official government and statutory
bodies. It will aim to provide a focus for independent analysis
and assessment of international policy and seek to promote
debate at a time when, despite the best efforts of the international
community, the drug problems confronting the world appear to
be more serious than at any time in the past 40 years.
This is a big challenge, but it is not an insurmountable one.
A drug free world is an impossible ideal. A world in which
far less harm is caused as a result of the production,
trafficking and consumption of drugs is both an inspiring
ideal and an achievable objective.
between different policy objectives – for example, to reduce
overall drug use or to reduce drug related crime – that may
be viewed differently in different countries. 
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THE BECKLEY FOUNDATION 
DRUG POLICY PROGRAMME
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widespread drug use and a commitment to pursue policies
that are effective.
6 That analysis of future policy options, while identifying
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‘correct’ policy on psycho-active drugs. What may be
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The Beckley Foundation Drug Policy Programme (BFDPP) is a
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review of global drug policy. The aim of this partnership
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The European Gateway on Alcohol, Drugs and Addictions,
which links to relevant websites across Europe is at
www.elisad.uni-bremen.de
The European Monitoring Centre for Drugs and Drug
Addiction site is at www.emcdda.eu.int 
The Forward Thinking of Drugs website is at www.forward-
thinking-on-drugs.org
The Organisation of American States website is at www.oas.org
The United Nations Office of Drugs and Crime website is at
www.unodc.org
FOOTNOTES
1 Committing itself to the slogan ‘a drug free world: we can do it!’, the UNGASS set
three targets for 2008, which were accepted by 150 countries: (i) ‘eliminating or
significantly reducing the cultivation of the coca bush, the cannabis plant and the opium
poppy’; (ii) ‘eliminating or significantly reducing the illicit manufacture, marketing and
trafficking of psychotropic substances, including synthetic drugs, and the diversion of
precursors; and (iii) ‘achieving significant and measurable results in the field of demand
reduction’. 
2 In his press comment on the publication of the EMCDDA’s 2003 Annual Report on
the Drug Situation in the EU and Norway.
3 Although there was a marked decline in world illicit opium and heroin production in
2001 this was largely as a result of internal political developments in Afghanistan. This
trend has been reversed with the resumption of large-scale opium poppy cultivation in
that country. It is a similar story for other illicit drugs (see UNODC, 2003).
4 These figures allow for poly-drug use (and, therefore, sum to more than 200 million). 
